Pharmacokinetics of IFX and TNF Concentrations in Serum, Stool, and Colonic Mucosa in Acute Severe Ulcerative Colitis



Status:Recruiting
Conditions:Colitis, Colitis, Gastrointestinal
Therapuetic Areas:Gastroenterology
Healthy:No
Age Range:18 - Any
Updated:3/28/2019
Start Date:December 21, 2018
End Date:December 2020
Contact:Lee Williamson
Email:leeanne.williamson@robartsinc.com
Phone:226-270-7674

Use our guide to learn which trials are right for you!

Pharmacokinetics of Infliximab and Tumor Necrosis Factor Concentrations in Serum, Stool, and Colonic Mucosa in Acute Severe Ulcerative Colitis

This is an open-label, prospective, observational study with the primary objective to
characterize the pharmacokinetics of infliximab in patients with Acute Severe Ulcerative
Colitis.

In Acute Severe Ulcerative Colitis (ASUC), drug exposure may be affected by intestinal
protein loss leading to hypoalbuminemia and rapid clearance of infliximab (IFX). Importantly,
2 studies have associated the loss of IFX in stool with poor outcomes. Multiple observational
studies have identified that patients with faster IFX clearance have worse clinical outcomes
and higher rates of antidrug antibody formation. To better understand optimal dosing of IFX
in ASUC, the pharmacokinetics of IFX in association with outcomes must be better defined in
this setting.

Inclusion Criteria:

- Present to hospital with ASUC based on Truelove and Witts criteria,33 defined as the
presence of more than 6 bloody stools per day along with any 1 of the following:
tachycardia > 90 beats per minute, fever > 37.8 °C, hemoglobin < 10.5 g/dL, and
erythrocyte sedimentation rate (ESR) > 30 mm/h (or CRP > 30 mg/L [high-sensitivity CRP
> 300 mg/L]) is a suitable surrogate if ESR is not available1).

- Have a partial MCS > 7.

- Have a Mayo Clinic ES ≥ 2 with disease extending 15 cm or more beyond the anal verge.

- Require rescue inpatient IFX infusion as part of routine care. Note, the IFX treatment
regimen is not defined by this protocol and any dosage regimen is acceptable for the
purposes of this study, such as standard or accelerated induction regimens.

- Be able to speak English and participate fully in all aspects of this clinical trial.

- Provide written informed consent.

Exclusion Criteria:

- A known history of being positive for anti-IFX antibodies.

- Have a serious active infection, active malignancy, or any other known condition
contraindicated with infliximab therapy, according to current prescribing information.

- Serious underlying disease other than ASUC, or other physical or psychosocial
condition that, in the opinion of the investigator, may interfere with the subject's
ability to participate fully in the study.

- Prior enrollment in the current study.
We found this trial at
2
sites
London, Ontario
Principal Investigator: Vipul Jairath
?
mi
from
London,
Click here to add this to my saved trials
San Diego, California 92103
Principal Investigator: Robert Battat
?
mi
from
San Diego, CA
Click here to add this to my saved trials